weight regain after stopping glp-1 agonists Two Years GLP-1s, Most Patients Sustain at Least Some Loss Weight maintenance after discontinuation of

The correct classification: Pure GLP-1 agonists: exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, efpeglenatide, orforglipron Dual GIP/GLP-1 agonists: tirzepatide Triple agonists (GIP/GLP-1/glucagon): retatrutide Retatrutide, approved in early 2026, adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism

Nerve Function Diabetic neuropathy nerve damage due to long-term high blood sugar is one of the most common and debilitating complications of diabetes

Yeah, probably

(2018) 49:560575.e6

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema

107, S308